An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Although mucosal healing (MH) has been considered a treatment goal for patients with ulcerative colitis (UC), the risk factors predictive of relapse in patients who achieve MH are unknown. Because the platelet count has been shown to be a marker of inflammation in inflammatory bowel diseases, this study aimed to assess whether the platelet count could predict relapse in UC patients with MH. Methods: A prospective observational study was performed. UC patients with MH were consecutively enrolled in the study and monitored for at least 2 years or until relapse. The correlation between the incidence of relapse and the platelet count at the time of study enrollment was examined. Results: In total, 43 patients were enrolled, and 14 patients (33%) relapsed. The median platelet count at the time of enrollment in the patients who relapsed significantly differed from that in the patients who did not relapse (27.2×104/μL vs 23.8×104/μL, respectively; p=0.016). A platelet count >25.0×104/μL was a significant risk factor for relapse based on a multivariate analysis (hazard ratio, 4.85; 95% confidence interval, 1.07 to 25.28), and according to the Kaplan-Meier analysis, this cutoff could identify patients susceptible to relapse (p=0.041, log-rank test). Conclusions: The platelet count could be used as a predictor of relapse in UC patients with MH.
Abstract
Background/Aims: Although mucosal healing (MH) has been considered a treatment goal for patients with ulcerative colitis (UC), the risk factors predictive of relapse in patients who achieve MH are unknown. Because the platelet count has been shown to be a marker of inflammation in inflammatory bowel diseases, this study aimed to assess whether the platelet count could predict relapse in UC patients with MH. Methods: A prospective observational study was performed. UC patients with MH were consecutively enrolled in the study and monitored for at least 2 years or until relapse. The correlation between the incidence of relapse and the platelet count at the time of study enrollment was examined. Results: In total, 43 patients were enrolled, and 14 patients (33%) relapsed. The median platelet count at the time of enrollment in the patients who relapsed significantly differed from that in the patients who did not relapse (27.2×104/μL vs 23.8×104/μL, respectively; p=0.016). A platelet count >25.0×104/μL was a significant risk factor for relapse based on a multivariate analysis (hazard ratio, 4.85; 95% confidence interval, 1.07 to 25.28), and according to the Kaplan-Meier analysis, this cutoff could identify patients susceptible to relapse (p=0.041, log-rank test). Conclusions: The platelet count could be used as a predictor of relapse in UC patients with MH.
참고문헌 (26)
- Peyrin-Biroulet L, "Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease", J Crohns Colitis, 5, pp.477~483 (2011)[DOI]
- Lobaton T, "A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis", Inflamm Bowel Dis, 19, pp.1034~1042 (2013)[DOI]
- Onal IK, "The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis", Turk J Gastroenterol, 23, pp.509~514 (2012)[DOI]
- Nakarai A, "Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test", Am J Gastroenterol, 108, pp.83~89 (2013)[DOI]
- Takashima S, "Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test", Am J Gastroenterol, 110, pp.873~880 (2015)[DOI]
- Solem CA, "Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease", Inflamm Bowel Dis, 11, pp.707~712 (2005)[DOI]
- Bitton A, "Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis", Gastroenterology, 120, pp.13~20 (2001)[DOI]
- Nakarai A, "Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count", World J Gastroenterol, 20, pp.18367~18374 (2014)[DOI]
- Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study", N Engl J Med, 317, pp.1625~1629 (1987)[DOI]
- Kapsoritakis AN, "Mean platelet volume: a useful marker of inflammatory bowel disease activity", Am J Gastroenterol, 96, pp.776~781 (2001)[DOI]
- Kayahan H, "Reticulated platelet levels in patients with ulcerative colitis", Int J Colorectal Dis, 22, pp.1429~1435 (2007)[DOI]
- Lefer AM, "Platelets: unindicted coconspirators in inflammatory tissue injury", Circ Res, 87, pp.1077~1078 (2000)[DOI]
- Rizvi M, "CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease", Trends Mol Med, 14, pp.530~538 (2008)[DOI]
- Khan SY, "Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury", Blood, 108, pp.2455~2462 (2006)[DOI]
- Phipps RP, "Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion", Lancet, 357, pp.2023~2024 (2001)[DOI]
- Danese S, "Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients", Gut, 52, pp.1435~1441 (2003)[DOI]
- Kayo S, "Close association between activated platelets and neutrophils in the active phase of ulcerative colitis in humans", Inflamm Bowel Dis, 12, pp.727~735 (2006)[DOI]
- Bessissow T, "Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing", Am J Gastroenterol, 107, pp.1684~1692 (2012)[DOI]
- Bryant RV, "Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up", Gut, 65, pp.408~414 (2016)[DOI]
- Christensen B, "Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes", Clin Gastroenterol Hepatol, 15, pp.1557~1564 (2017)[DOI]
- Mooiweer E, "Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission", J Crohns Colitis, 9, pp.50~55 (2015)[DOI]
- Barreiro-de Acosta M, "Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study", J Crohns Colitis, 10, pp.13~19 (2016)[DOI]
- Jauregui-Amezaga A, "Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study", Inflamm Bowel Dis, 20, pp.1187~1193 (2014)[DOI]
- Yokoyama K, "Clinical study of the relation between mucosal healing and longterm outcomes in ulcerative colitis", Gastroenterol Res Pract, 2013, pp.192794~ (2013)
- Voudoukis E, "Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease", Eur J Gastroenterol Hepatol, 25, pp.1212~1216 (2013)
- Kulnigg-Dabsch S, "Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia", PLoS One, 7, pp.e34520~ (2012)[DOI]